In a world where misinformation spreads like wildfire, the story of leucovorin and its connection to autism is a cautionary tale. It's a narrative that highlights the power of influence, the desperation of parents seeking answers, and the need for rigorous scientific evidence.
The Rise of Leucovorin
Last September, an unlikely alliance between President Trump and Robert F. Kennedy Jr. brought leucovorin, an existing medication, into the spotlight as a potential treatment for autism spectrum disorder (ASD). The announcement, which also implicated acetaminophen (Tylenol) in autism risk, sent shockwaves through the medical community and beyond.
What makes this particularly fascinating is the chain reaction it set off. Despite a lack of substantial evidence, the endorsement from such high-profile figures seemed to have a profound impact on families affected by autism.
The Trump Effect
Researchers at the University of California, San Diego, decided to investigate this phenomenon. They analyzed prescription trends for leucovorin among children with autism and found a startling result. The prescription rate skyrocketed, especially after the September announcement.
"The Trump endorsement had a significant influence," says lead researcher Joshua Rothman. "Families are desperate for therapies, especially when options are limited."
A Fox News Factor
But the Trump announcement wasn't the only catalyst. A Fox News report in February 2025, detailing families' belief in leucovorin's benefits, also contributed to the drug's rising popularity.
"We saw a clear bump after the Fox News report, followed by an even larger spike post-Trump," Rothman explains. The prescription rate increased over 2,000% within a year, a staggering figure.
The Data Dilemma
Here's where things get interesting. While the demand for leucovorin soared, the scientific evidence supporting its use for autism remained weak. In fact, it has only gotten weaker since the September announcement.
"The data has always been tenuous," Rothman notes. "And now, with the largest trial to date retracted due to errors, the evidence is even more questionable."
A Call for Action
Despite the lack of strong data, the fact remains that many families have been prescribed leucovorin. Rothman argues that this situation demands further research.
"With so many families now using leucovorin, we need to assess the outcomes and share the results. It's our duty as scientists to provide the necessary evidence for informed decision-making."
A Broader Perspective
This story raises important questions about the influence of media and public figures on medical decisions. It also highlights the vulnerability of families seeking hope and the need for accessible, reliable information.
In my opinion, it's a reminder that in the quest for answers, we must always prioritize evidence-based practices. The leucovorin saga serves as a cautionary tale, urging us to think critically and demand rigorous scientific scrutiny.
